Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 247

The DOI matches its Crossref record.

The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitis

Open access
Sandborn, W. J., Hanauer, S. B.·2003·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Aim : To quantify through systematic review the pharmacokinetic profiles of the oral delayed release and sustained release mesalazine (5‐aminosalicylate, 5ASA) formulations (Asacol, Salofalk, Mesasal, Claversal, Pentasa) and pro‐drugs (sulfasalazine, olsalazine, balsalazide) used in the management of ulcerative colitis. Methods : Selected articles had: (1) adult healthy volunteers or patients with ulcerative colitis and (2) quantification of pharmacokinetic data to include, at a minimum, urinary excretion of total 5ASA [5ASA plus N‐Acetyl‐5ASA (N‐Ac‐5ASA)]. Data collection and analysis : Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N‐Acetyl‐5ASA, total 5ASA, and the parent pro‐drug compounds was extracted. Main results : The summary results for urinary excretion of total 5ASA over 24–96 h in all subjects (either mean or median) were: sulfasalazine mean 11–33% or median 22%; olsalazine mean 14–31% or median 16–27%; balsalazide mean 12–35% or median 20%; Asacol mean 10–35% or median 18–40%; Pentasa mean 15–53% or median 23–34%; Salofalk, Mesasal and Claversal mean 27–56% or median 31–44%. The summary results for faecal excretion of total 5ASA over 24–96 h in all subjects (either mean or median) were: sulfasalazine mean 23–75% or median 38%; olsalazine mean 47–50% or median 17–36%; balsalazide mean 46% or median 22%; Asacol mean 40–64% or median 20–56%; Pentasa mean 12–51% or median 39–59%; Salofalk, Mesasal and Claversal mean 37–44% or median 23–35%. Conclusions : The systemic exposure to 5ASA, as measured by urinary excretion of total 5ASA, and the faecal excretion of total 5ASA is comparable for all oral mesalazine formulations and pro‐drugs. Thus, selection of a mesalazine therapy for the treatment of ulcerative colitis should be based on other factors such as efficacy, dose–response, toxicity of the parent compound and its metabolites, compliance issues related to dose forms and dosing schedules, and costs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2003.01408.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 247

Metadata

Authors
Sandborn, W. J., & Hanauer, S. B.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2002-12-19
Volume
17
Issue
1
Pages
29-42
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2147825834
Cited by
247
References
0
FWCI
5.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitis. https://app.cochat.ai/papers/10.1046/j.1365-2036.2003.01408.x
The paper
Sandborn, W. J., & Hanauer, S. B. (2003). The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2003.01408.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.